Updated Glioblastoma Data Demonstrated Median OS of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence of γδ T cells in patients receiving multiple doses. Importantly, across our clinical experience, we have not observed any CRS, ICANS, major infections or treatment-related serious adverse events. These data continue to underscore the potential of γδ T cell-based therapies to provide meaningful clinical benefit for patients.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib

“Endocrine therapy remains the backbone of treatment in HR+/HER2- breast cancer, and resistance driven by the PI3K/AKT/mTOR pathway is one of the central problems in this setting,” said Anand Parikh, Chief Executive Officer of Faeth Therapeutics. “We believe PIKTOR’s multi-node approach to this pathway is well suited to patients whose